<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedBookArticle><BookDocument><PMID Version="1">30000710</PMID><ArticleIdList><ArticleId IdType="bookaccession">NBK501649</ArticleId></ArticleIdList><Book><Publisher><PublisherName>National Library of Medicine (US)</PublisherName><PublisherLocation>Bethesda (MD)</PublisherLocation></Publisher><BookTitle book="lactmed">Drugs and Lactation Database (LactMed)</BookTitle><PubDate><Year>2006</Year></PubDate><BeginningDate><Year>2006</Year></BeginningDate><Medium>Internet</Medium></Book><ArticleTitle book="lactmed" part="LM749">Saxagliptin</ArticleTitle><Language>eng</Language><PublicationType UI="D016454">Review</PublicationType><Abstract><AbstractText>No information is available on the clinical use of saxagliptin during breastfeeding. Saxagliptin has a shorter half-life than the other dipeptidyl-peptidase IV inhibitors, so it might be a better choice among drugs in this class for nursing mothers. Monitoring of the breastfed infant's blood glucose is advisable during maternal therapy with saxagliptin.[1] However, an alternate drug may be preferred, especially while nursing a newborn or preterm infant.</AbstractText></Abstract><Sections><Section><SectionTitle book="lactmed" part="LM749" sec="LM749.drug-levels-effects">Drug Levels and Effects</SectionTitle></Section><Section><SectionTitle book="lactmed" part="LM749" sec="LM749.subst-id">Substance Identification</SectionTitle></Section></Sections><KeywordList Owner="NLM"><Keyword MajorTopicYN="N">Saxagliptin hydrate</Keyword><Keyword MajorTopicYN="N">Saxagliptin</Keyword><Keyword MajorTopicYN="N">Onglyza</Keyword><Keyword MajorTopicYN="N">UNII-9GB927LAJW</Keyword><Keyword MajorTopicYN="N">9GB927LAJW</Keyword><Keyword MajorTopicYN="N">Saxagliptin [USAN:INN:BAN]</Keyword><Keyword MajorTopicYN="N">945667-22-1</Keyword><Keyword MajorTopicYN="N">BMS-477118-11</Keyword><Keyword MajorTopicYN="N">(1S,3S,5S)-2-((2S)-Amino(3-hydroxytricyclo(3.3.1.13,7)dec-1-yl)acetyl)2- azabicyclo(3.1.0)hexane-3-carbonitrile monohydrate</Keyword><Keyword MajorTopicYN="N">2-Azabicyclo(3.1.0)hexane-3-carbonitrile, 2-((2S)-2-amino-2-(3-hydroxytricyclo(3.3.1.13,7)dec-1-yl)acetyl)-, hydrate (1:1), (1S,3S,5S)-</Keyword></KeywordList><ContributionDate><Year>2019</Year><Month>2</Month><Day>7</Day></ContributionDate><ReferenceList><Reference><Citation>Berlin CM, Briggs GG. Drugs and chemicals in human milk. Semin Fetal Neonatal Med. 2005;10: 149-59.</Citation><ArticleIdList><ArticleId IdType="pubmed">15701580</ArticleId></ArticleIdList></Reference></ReferenceList></BookDocument><PubmedBookData><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30000710</ArticleId></ArticleIdList></PubmedBookData></PubmedBookArticle></PubmedArticleSet>
